Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial.

Name: Kaimen Rigor review — Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial.
Item: Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial.
Rating: 94
Author: Alpha1

Loi S, Salgado R, Curigliano G, Romero Díaz RI, Delaloge S, Rojas García CI, Kok M, Saura C, Harbeck N, Mittendorf EA, Yardley DA, Suárez Zaizar A, Caminos FR, Ungureanu A, Reinoso-Toledo JG, Guarneri V, Egle D, Ades F, Pacius M, Chhibber A, Chandra R, Nathani R, Spires T, Wu JQ, Pusztai L, McArthur H

Paper source

Read full text (PMC)

Embed this Rigor badge

Kaimen Rigor review — 1.25★ (Critical), 0 critical, 2 high issues for “Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial.”

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 15, 2026

Read alongside

Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial.

Read full text (PMC)

DOI

10.1038/s41591-024-03414-8

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/aae1b556-5a53-4eb7-a982-6ed5a3fa2061" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/aae1b556-5a53-4eb7-a982-6ed5a3fa2061/badge" alt="Kaimen Rigor review — 1.25★ (Critical), 0 critical, 2 high issues for “Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

0f628449e7bf618ef441fdd4cc8227da3dd33e9190fe2d277c3dbf8a2226e180

Verify via API

Issued Aug 15, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Alpha¹ by Kaimen

Fetching the latest research

Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial.

Paper source

Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial.

Read full text (PMC)

Embed this Rigor badge

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 15, 2026

Kaimen Rigor review

Kaimen Rigor reviewed

1.25 / 5

Critical — serious problems across many checks

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×3−1.5★
ClaimsOverstated claim ×2−1★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary endpoint is pathological complete response (pCR), a surrogate for long-term clinical outcomes such as event-free survival (EFS). The paper does not demonstrate target engagement at the tested dose (no PK/PD data) and does not cite validated evidence linking pCR to EFS in this specific setting; it only mentions that pCR is associated with improved long-term outcomes in ER+/HER2− BC, but this is not a validated surrogate for the efficacy claim.
“The primary endpoint of pCR was significantly higher in the nivolumab arm compared with placebo (24.5% versus 13.8%; P = 0.0021)”
Find in source
02Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The effect size is reported as an absolute difference of 10.7% in pCR rates (24.5% vs 13.8%), which is statistically significant but not anchored to a minimal clinically important difference or to long-term clinical benefit. The paper acknowledges that the study is underpowered for EFS and that follow-up is too short to draw conclusions, so the clinical meaningfulness of the pCR improvement is not established.
“Because of its early termination, the study was significantly underpowered for event-free survival (EFS), and median follow-up for EFS in the mITT population at reporting was premature at 19 months, with a low number of events observed.”
Find in source
03Conclusion reaches beyond the evidence
mediumOverreachreviewer-assessedFull detail
The results suggest a new treatment paradigm that emphasizes the role of immunotherapy in luminal disease.
“These findings reshape our understanding of this disease in the context of T cell immunosurveillance and immunotherapy response in luminal disease.”
DiscussionFind in source
04Conclusion reaches beyond the evidence
mediumOverreachreviewer-assessedFull detail
The results suggest a new treatment paradigm emphasizing the role of immunotherapy in luminal disease.
“These results represent a new milestone in the neoadjuvant treatment of ER+/HER2− BC”
DiscussionFind in source

Findings by category

101ArithmeticNumerical inconsistencies 402OverreachOverstated conclusions 03AuthenticityNone found 104DisclosureReporting gaps 05AvailabilityNone found 06Copyedit6 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and well-reported phase 3 randomized trial with strong methodology across most dimensions. The main weakness is the vague data availability statement, which lacks a concrete access mechanism. Minor reporting gaps include unspecified statistical software and lack of explicit CONSORT adherence.

Both reviewers agreed on study type (interventional). The evaluation covered all eight dimensions; several sub-criteria were not applicable (e.g., animal-related criteria, code sharing). The statistics verification checked only 1 test (limited coverage), and the citation check found no retracted or missing references. The reviewers diverged on data code availability (pass vs. warn) and on a few sub-criteria (limitations addressed, outlier handling), which were resolved by weighing the evidence.

Numerical inconsistencies

1 finding · worst low

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Recomputed 1 test: 1 consistent, 0 inconsistent; 1 via agent-written checks.

Overstated conclusions

4 findings · worst high

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions overstated beyond the evidenceAssessed
Conclusions only partially backed by the presented evidenceAssessed

8 major claims checked against the paper's own evidence: 2 not fully backed by the presented evidence (unsupported or overstated), 1 only partially supported (evidence backs part of the claim; gaps or caveats remain).

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Data authenticity concerns

None found

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Checked — nothing surfaced.

Reporting gaps

1 finding · worst medium

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

Eight Dimensions7 pass · 1 warn

The introduction cites prior research on ER+/HER2- breast cancer heterogeneity, the role of lymphocytic infiltration, and results from I-SPY2 and KEYNOTE-756, providing a strong foundation. The hypothesis that adding anti-PD-1 to chemotherapy increases pCR rates is logically derived from this evidence. Limitations of prior research are implicitly addressed by the trial's design and biomarker analyses.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise with prior work cited and a logical rationale for the hypothesis.

Evidence

“ER+/HER2− BC exhibits significant heterogeneity in its responses to treatment and clinical outcomes, posing substantial challenges for effective management.”

Introduction ¶1Find in source

“We hypothesized that addition of an anti-programmed death 1 agent may increase pCR rates in this BC subtype.”

AbstractFind in source

“Results from the adaptively randomized I-SPY2 study suggest that anti-PD-(L)1 agents have the potential to increase the proportion of patients with high-risk ER+/HER2− BC who achieve pCR or minimal residual disease”

Introduction ¶3Find in source

PASSReviewer 2· 90% conf

The study clearly establishes its scientific premise with prior work and a logical rationale for testing nivolumab in ER+/HER2- breast cancer.

Evidence

“ER+/HER2− BC exhibits significant heterogeneity in its responses to treatment and clinical outcomes, posing substantial challenges for effective management.”

Introduction ¶1Find in source

“We hypothesized that addition of an anti-programmed death 1 agent may increase pCR rates in this BC subtype.”

AbstractFind in source

Introduction ¶3Find in source

Randomization method (interactive response technology) and stratification factors are described. Blinding is double-blind, and the open-label adjuvant phase is explained. Power analysis is provided (87% power, 10% difference). Inclusion/exclusion criteria are detailed. Outlier handling is addressed via the mITT population and missing data due to site closure. Controls are the placebo arm. Independent replication is not applicable for a single pivotal trial.

Sub-criteria

controlsADEQUATE

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial design is rigorous with adequate randomization, blinding, power analysis, and pre-specified endpoints.

Evidence

paraphrase[Methods, Trial design and treatments]

“Randomization was stratified per interactive response technology by the proportion of PD-L1-expressing immune cells ... tumor grade ... axillary nodal status ... and anthracycline dosing frequency.”

“a sample size of 521 patients in the intent-to-treat population would yield approximately 87% power (two-sided alpha of 0.05) to detect a difference of 10% in pCR rates between treatment arms”

Statistical analysisFind in source

“CheckMate 7FL was a prospective, randomized, multicenter, double-blind, placebo-controlled phase 3 trial”

MethodsFind in source

PASSReviewer 2· 95% conf

The trial design is rigorous with adequate randomization, blinding, power analysis, and inclusion/exclusion criteria.

Evidence

“Randomization was stratified per interactive response technology by the proportion of PD-L1-expressing immune cells (percentage of immune cells by VENTANA PD-L1 SP142 immunohistochemistry, cutoff at 1%), tumor grade (2 or 3), pathologically confirmed axillary nodal status (positive on pathological review or negative on radiographic and/or pathologic review) and anthracycline dosing frequency (every 3 weeks or every 2 weeks).”

MethodsFind in source

“CheckMate 7FL was a prospective, randomized, multicenter, double-blind, placebo-controlled phase 3 trial”

MethodsFind in source

“Based on the normal approximation to the binomial, a sample size of 521 patients in the intent-to-treat population would yield approximately 87% power (two-sided alpha of 0.05) to detect a difference of 10% in pCR rates between treatment arms, assuming a 12% pCR rate in the control arm.”

Statistical analysisFind in source

Sex is reported (all female in nivolumab arm, 99.6% in placebo). Age is reported with median and range. Health status is captured via ECOG PS. Demographics include tumor grade, stage, nodal status, and PD-L1 status. Species/strain and housing are not applicable for a human trial.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Biological variables are well reported for a human trial, including sex, age, and key clinical characteristics.

Evidence

“Female | 257 (100) | 169 (100) | 88 (100) | 252 (99.6) | 168 (99.4) | 84 (100)”

Table 1Find in source

“Median age, years (range) | 50 (24–78) | 51 (24–77) | 49 (28–78) | 51 (23–79) | 51 (23–79) | 51 (27–78)”

Table 1Find in source

paraphrase[Table 1]

“ECOG PS | 0 | 221 (86) | 144 (85) | 77 (88) | 222 (88) | 146 (86) | 76 (91)”

PASSReviewer 2· 90% conf

Biological variables are well reported for a human trial, including sex, age, and demographics.

Evidence

“Female | 257 (100) | 169 (100) | 88 (100) | 252 (99.6) | 168 (99.4) | 84 (100)”

Table 1Find in source

“Median age, years (range) | 50 (24–78) | 51 (24–77) | 49 (28–78) | 51 (23–79) | 51 (23–79) | 51 (27–78)”

Table 1Find in source

paraphrase[Table 1]

“ECOG PS | 0 | 221 (86) | 144 (85) | 77 (88) | 222 (88) | 146 (86) | 76 (91)”

The trial protocol was approved by the appropriate ethics body at each participating site, and all patients provided written informed consent. Compliance with Good Clinical Practice is stated. The ethics statement is adequate as it names the approving bodies (ethics body at each site) and consent is described.

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Ethical approvals and consent are adequately reported.

Evidence

“The trial protocol and amendments were approved by the appropriate ethics body at each participating site.”

MethodsFind in source

“All patients provided written informed consent.”

MethodsFind in source

“All authors confirm that the trial was conducted with respect to the standards of Good Clinical Practice.”

MethodsFind in source

PASSReviewer 2· 95% conf

Ethical approvals and consent are adequately reported.

Evidence

“The trial protocol and amendments were approved by the appropriate ethics body at each participating site.”

MethodsFind in source

“All patients provided written informed consent.”

MethodsFind in source

“All authors confirm that the trial was conducted with respect to the standards of Good Clinical Practice.”

MethodsFind in source

The investigational product (nivolumab) is identified with dose and regimen. The placebo is mentioned. Key assays (VENTANA SP142, Dako 28-8) are identified with manufacturers. Software tools are not explicitly named, but the statistical methods are described. Other bench resources are not applicable.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedINADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Key resources, particularly the investigational product and assays, are adequately identified.

Evidence

“patients were randomized 1:1 to receive either nivolumab 360 mg or placebo every 3 weeks with weekly paclitaxel for 12 weeks.”

MethodsFind in source

“PD-L1 was evaluated by qualitative immunohistochemistry on immune cells with the VENTANA SP142 assay (Roche Diagnostics) and PD-L1 CPS with the 28-8 pharmDx assay (Agilent).”

MethodsFind in source

absence[Methods, Statistical analyses]

Statistical software is not explicitly named.

PASSReviewer 2· 90% conf

Key resources, including the investigational drug and assays, are adequately identified.

Evidence

“patients were randomized 1:1 to receive either nivolumab 360 mg or placebo every 3 weeks with weekly paclitaxel for 12 weeks.”

MethodsFind in source

“PD-L1 was evaluated by qualitative immunohistochemistry on immune cells with the VENTANA SP142 assay (Roche Diagnostics) and PD-L1 CPS with the 28-8 pharmDx assay (Agilent).”

MethodsFind in source

“ER and Ki67 expression were centrally evaluated using Agilent MIB-Dako pharmDx immunohistochemistry.”

MethodsFind in source

Tests are named (Cochran-Mantel-Haenszel, Mantel-Haenszel, Clopper-Pearson, Newcombe). Exact p-values are reported (P = 0.0021). Effect sizes with CIs are provided (OR 2.05, 95% CI 1.29-3.27). Software is not identified, but this is a minor omission. Data presentation includes forest plots and CIs. Mathematical plausibility checks are not applicable for large-N continuous outcomes.

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedINADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical analysis is rigorous with named tests, exact p-values, and effect sizes with CIs.

Evidence

“Strata-adjusted difference in pCR rate between the two arms was analyzed with the stratified Cochran–Mantel–Haenszel method of weighting with a two-sided alpha level of 0.05.”

Statistical analysisFind in source

“odds ratio (OR) 2.05 (95% confidence interval (CI) 1.29 to 3.27, P = 0.0021)”

ResultsFind in source

“odds ratio (OR) 2.05 (95% confidence interval (CI) 1.29 to 3.27, P = 0.0021)”

ResultsFind in source

PASSReviewer 2· 90% conf

Statistical analysis is well described with named tests, effect sizes with CIs, and adequate data presentation.

Evidence

“Strata-adjusted difference in pCR rate between the two arms was analyzed with the stratified Cochran–Mantel–Haenszel method of weighting with a two-sided alpha level of 0.05.”

Statistical analysisFind in source

“24.5%, 63 of 257) versus placebo (13.8%, 35 of 253; odds ratio (OR) 2.05 (95% confidence interval (CI) 1.29 to 3.27, P = 0.0021)”

ResultsFind in source

“odds ratio (OR) 2.05 (95% confidence interval (CI) 1.29 to 3.27, P = 0.0021)”

ResultsFind in source

The data availability statement says Bristol Myers Squibb will honor legitimate requests for clinical trial data from qualified researchers, but does not specify a platform or timeframe. This is reported_but_inadequate. Repository deposit and accession numbers are not applicable for patient-level data. Code sharing is not applicable as no bespoke code is mentioned.

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositN/A

data availability statementINADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Data availability is adequately described with a concrete access mechanism.

Evidence

“Bristol Myers Squibb will honor legitimate requests for clinical trial data from qualified researchers with a clearly defined scientific objective.”

Data availabilityFind in source

WARNReviewer 2· 85% conf

Data availability statement is present but vague, lacking a concrete access mechanism.

Evidence

“Bristol Myers Squibb will honor legitimate requests for clinical trial data from qualified researchers with a clearly defined scientific objective.”

Data availabilityFind in source

The trial is registered (NCT04109066). Methods are detailed. Limitations are discussed (underpowered EFS, protocol amendment). Conclusions are proportional, acknowledging the need for longer follow-up. Funding and competing interests are disclosed. A reporting guideline is not explicitly mentioned, but the paper follows CONSORT-like structure.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineINADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Reporting is transparent with trial registration, limitations, and proportional conclusions.

Evidence

“Clinical trials.gov identifier: NCT04109066”

AbstractFind in source

“Limitations include the major protocol amendment that significantly reduced the sample size and/or number of events and follow-up time resulting in EFS being designated as an exploratory endpoint.”

DiscussionFind in source

“This study was sponsored and funded by Bristol Myers Squibb”

AcknowledgementsFind in source

PASSReviewer 2· 90% conf

Reporting is transparent with trial registration, limitations discussed, and proportional conclusions.

Evidence

“Clinical trials.gov identifier: NCT04109066 (https://clinicaltrials.gov/study/NCT04109066)”

AbstractFind in source

DiscussionFind in source

“This study was sponsored and funded by Bristol Myers Squibb”

AcknowledgementsFind in source

Registered (1 ID: ClinicalTrials.gov). No reporting guideline cited.

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 33 references by DOI: 31 verified — 2 no DOI (shown, not verified).

2 data/code links checked; 2 live.

Copyediting

6 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 6 minor suggestions below.

6 copyedit issues flagged: mostly consistency, clarity, typo.

Kaimen Rigor Action ItemsFinal pass before journal submission

The published work is robust and generally well-reported, but an informed reader should weigh the vague data availability statement and the lack of explicit statistical software identification. The claim of a 'new treatment paradigm' is somewhat overstated given the short follow-up and exploratory EFS; a correction or clarification may be warranted. No critical validity threats were identified.

1.
HIGHdata code
In the Data availability section, specify a concrete access mechanism (e.g., a data-sharing platform like Vivli or a data access committee) and the timeframe for responding to requests.
The current statement is vague and does not provide a clear route for qualified researchers to obtain the data, which is a reporting gap.
2.
HIGHreporting
In the Discussion, temper the claim of a 'new treatment paradigm' to reflect that long-term benefit (EFS) is not yet established due to short follow-up and the exploratory nature of EFS.
The claim is overstated given the evidence; the paper itself notes longer follow-up is needed.
3.
MEDIUMreporting
In the Methods, explicitly name the statistical software (e.g., SAS version, R version) used for analyses.
This improves reproducibility and was flagged by both reviewers as a minor omission.
4.
MEDIUMreporting
In the Methods or Reporting Summary, explicitly state adherence to CONSORT guidelines for reporting randomized trials, or provide the completed CONSORT checklist.
This strengthens the reporting transparency and is a common expectation for RCTs.
5.
MEDIUMreporting
In the Discussion, add a sentence acknowledging the lack of independent replication of the biomarker findings.
This addresses the limitations_addressed criterion and provides a more balanced interpretation.
6.
MEDIUMreporting
In the Methods, clarify how outliers or missing data were handled in the analysis (e.g., imputation methods) beyond the exclusion of 11 patients due to site closure.
This strengthens the outlier_handling criterion and transparency.
7.
MEDIUMdata code
In the Data availability section, mention whether the study protocol and statistical analysis plan are available in a public repository.
This would allow independent verification of pre-specified analyses.
8.
MEDIUMreporting
In the Results, report the number of patients with missing biomarker data for each assay to enhance transparency.
This helps readers assess potential bias in biomarker analyses.
9.
LOWcopyedit
In the Abstract, change 'Clinical trials.gov identifier' to 'ClinicalTrials.gov identifier' for consistency.
Minor capitalization inconsistency flagged by the copyedit pass.
10.
LOWcopyedit
In the Methods, add a reference for the safety concern about combining abemaciclib with nivolumab.
The statement is unsupported without a citation.
11.
LOWcopyedit
In Table 1, ensure the formatting is consistent, particularly the PD-L1+ columns for the placebo arm.
The table appears to have missing cells, which could confuse readers.
12.
LOWcopyedit
In the Results, clarify the definition of PD-L1+ tumors to avoid redundancy.
Minor wording redundancy flagged by the copyedit pass.

Full text (52,423 chars)Analyzed: Aug 15, 2026

Start the discussion on JRNLClub

Community discussion on jrnlclub.com

Read alongside

Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial.

Read full text (PMC)

DOI

10.1038/s41591-024-03414-8

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/aae1b556-5a53-4eb7-a982-6ed5a3fa2061" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/aae1b556-5a53-4eb7-a982-6ed5a3fa2061/badge" alt="Kaimen Rigor review — 1.25★ (Critical), 0 critical, 2 high issues for “Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

0f628449e7bf618ef441fdd4cc8227da3dd33e9190fe2d277c3dbf8a2226e180

Verify via API

Issued Aug 15, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Kaimen Rigor review

Kaimen Rigor reviewed

1.25 / 5

Critical — serious problems across many checks

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×3−1.5★
ClaimsOverstated claim ×2−1★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary endpoint is pathological complete response (pCR), a surrogate for long-term clinical outcomes such as event-free survival (EFS). The paper does not demonstrate target engagement at the tested dose (no PK/PD data) and does not cite validated evidence linking pCR to EFS in this specific setting; it only mentions that pCR is associated with improved long-term outcomes in ER+/HER2− BC, but this is not a validated surrogate for the efficacy claim.
“The primary endpoint of pCR was significantly higher in the nivolumab arm compared with placebo (24.5% versus 13.8%; P = 0.0021)”
Find in source
02Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The effect size is reported as an absolute difference of 10.7% in pCR rates (24.5% vs 13.8%), which is statistically significant but not anchored to a minimal clinically important difference or to long-term clinical benefit. The paper acknowledges that the study is underpowered for EFS and that follow-up is too short to draw conclusions, so the clinical meaningfulness of the pCR improvement is not established.
“Because of its early termination, the study was significantly underpowered for event-free survival (EFS), and median follow-up for EFS in the mITT population at reporting was premature at 19 months, with a low number of events observed.”
Find in source
03Conclusion reaches beyond the evidence
mediumOverreachreviewer-assessedFull detail
The results suggest a new treatment paradigm that emphasizes the role of immunotherapy in luminal disease.
“These findings reshape our understanding of this disease in the context of T cell immunosurveillance and immunotherapy response in luminal disease.”
DiscussionFind in source
04Conclusion reaches beyond the evidence
mediumOverreachreviewer-assessedFull detail
The results suggest a new treatment paradigm emphasizing the role of immunotherapy in luminal disease.
“These results represent a new milestone in the neoadjuvant treatment of ER+/HER2− BC”
DiscussionFind in source

Findings by category

101ArithmeticNumerical inconsistencies 402OverreachOverstated conclusions 03AuthenticityNone found 104DisclosureReporting gaps 05AvailabilityNone found 06Copyedit6 minor suggestions

Numerical inconsistencies

1 finding · worst low

Internal contradictions in the reported numbersAssessed

Recomputed 1 test: 1 consistent, 0 inconsistent; 1 via agent-written checks.

Overstated conclusions

4 findings · worst high

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions overstated beyond the evidenceAssessed
Conclusions only partially backed by the presented evidenceAssessed

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Data authenticity concerns

None found

Checked — nothing surfaced.

Reporting gaps

1 finding · worst medium

Data/code availability incompleteAssessed

Eight Dimensions7 pass · 1 warn

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise with prior work cited and a logical rationale for the hypothesis.

Evidence

“ER+/HER2− BC exhibits significant heterogeneity in its responses to treatment and clinical outcomes, posing substantial challenges for effective management.”

Introduction ¶1Find in source

“We hypothesized that addition of an anti-programmed death 1 agent may increase pCR rates in this BC subtype.”

AbstractFind in source

Introduction ¶3Find in source

PASSReviewer 2· 90% conf

The study clearly establishes its scientific premise with prior work and a logical rationale for testing nivolumab in ER+/HER2- breast cancer.

Evidence

“ER+/HER2− BC exhibits significant heterogeneity in its responses to treatment and clinical outcomes, posing substantial challenges for effective management.”

Introduction ¶1Find in source

“We hypothesized that addition of an anti-programmed death 1 agent may increase pCR rates in this BC subtype.”

AbstractFind in source

Introduction ¶3Find in source

Sub-criteria

controlsADEQUATE

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial design is rigorous with adequate randomization, blinding, power analysis, and pre-specified endpoints.

Evidence

paraphrase[Methods, Trial design and treatments]

“a sample size of 521 patients in the intent-to-treat population would yield approximately 87% power (two-sided alpha of 0.05) to detect a difference of 10% in pCR rates between treatment arms”

Statistical analysisFind in source

“CheckMate 7FL was a prospective, randomized, multicenter, double-blind, placebo-controlled phase 3 trial”

MethodsFind in source

PASSReviewer 2· 95% conf

The trial design is rigorous with adequate randomization, blinding, power analysis, and inclusion/exclusion criteria.

Evidence

MethodsFind in source

“CheckMate 7FL was a prospective, randomized, multicenter, double-blind, placebo-controlled phase 3 trial”

MethodsFind in source

Statistical analysisFind in source

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Biological variables are well reported for a human trial, including sex, age, and key clinical characteristics.

Evidence

“Female | 257 (100) | 169 (100) | 88 (100) | 252 (99.6) | 168 (99.4) | 84 (100)”

Table 1Find in source

“Median age, years (range) | 50 (24–78) | 51 (24–77) | 49 (28–78) | 51 (23–79) | 51 (23–79) | 51 (27–78)”

Table 1Find in source

paraphrase[Table 1]

“ECOG PS | 0 | 221 (86) | 144 (85) | 77 (88) | 222 (88) | 146 (86) | 76 (91)”

PASSReviewer 2· 90% conf

Biological variables are well reported for a human trial, including sex, age, and demographics.

Evidence

“Female | 257 (100) | 169 (100) | 88 (100) | 252 (99.6) | 168 (99.4) | 84 (100)”

Table 1Find in source

“Median age, years (range) | 50 (24–78) | 51 (24–77) | 49 (28–78) | 51 (23–79) | 51 (23–79) | 51 (27–78)”

Table 1Find in source

paraphrase[Table 1]

“ECOG PS | 0 | 221 (86) | 144 (85) | 77 (88) | 222 (88) | 146 (86) | 76 (91)”

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Ethical approvals and consent are adequately reported.

Evidence

“The trial protocol and amendments were approved by the appropriate ethics body at each participating site.”

MethodsFind in source

“All patients provided written informed consent.”

MethodsFind in source

“All authors confirm that the trial was conducted with respect to the standards of Good Clinical Practice.”

MethodsFind in source

PASSReviewer 2· 95% conf

Ethical approvals and consent are adequately reported.

Evidence

“The trial protocol and amendments were approved by the appropriate ethics body at each participating site.”

MethodsFind in source

“All patients provided written informed consent.”

MethodsFind in source

“All authors confirm that the trial was conducted with respect to the standards of Good Clinical Practice.”

MethodsFind in source

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedINADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Key resources, particularly the investigational product and assays, are adequately identified.

Evidence

“patients were randomized 1:1 to receive either nivolumab 360 mg or placebo every 3 weeks with weekly paclitaxel for 12 weeks.”

MethodsFind in source

“PD-L1 was evaluated by qualitative immunohistochemistry on immune cells with the VENTANA SP142 assay (Roche Diagnostics) and PD-L1 CPS with the 28-8 pharmDx assay (Agilent).”

MethodsFind in source

absence[Methods, Statistical analyses]

Statistical software is not explicitly named.

PASSReviewer 2· 90% conf

Key resources, including the investigational drug and assays, are adequately identified.

Evidence

“patients were randomized 1:1 to receive either nivolumab 360 mg or placebo every 3 weeks with weekly paclitaxel for 12 weeks.”

MethodsFind in source

“PD-L1 was evaluated by qualitative immunohistochemistry on immune cells with the VENTANA SP142 assay (Roche Diagnostics) and PD-L1 CPS with the 28-8 pharmDx assay (Agilent).”

MethodsFind in source

“ER and Ki67 expression were centrally evaluated using Agilent MIB-Dako pharmDx immunohistochemistry.”

MethodsFind in source

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedINADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical analysis is rigorous with named tests, exact p-values, and effect sizes with CIs.

Evidence

“Strata-adjusted difference in pCR rate between the two arms was analyzed with the stratified Cochran–Mantel–Haenszel method of weighting with a two-sided alpha level of 0.05.”

Statistical analysisFind in source

“odds ratio (OR) 2.05 (95% confidence interval (CI) 1.29 to 3.27, P = 0.0021)”

ResultsFind in source

“odds ratio (OR) 2.05 (95% confidence interval (CI) 1.29 to 3.27, P = 0.0021)”

ResultsFind in source

PASSReviewer 2· 90% conf

Statistical analysis is well described with named tests, effect sizes with CIs, and adequate data presentation.

Evidence

“Strata-adjusted difference in pCR rate between the two arms was analyzed with the stratified Cochran–Mantel–Haenszel method of weighting with a two-sided alpha level of 0.05.”

Statistical analysisFind in source

“24.5%, 63 of 257) versus placebo (13.8%, 35 of 253; odds ratio (OR) 2.05 (95% confidence interval (CI) 1.29 to 3.27, P = 0.0021)”

ResultsFind in source

“odds ratio (OR) 2.05 (95% confidence interval (CI) 1.29 to 3.27, P = 0.0021)”

ResultsFind in source

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositN/A

data availability statementINADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Data availability is adequately described with a concrete access mechanism.

Evidence

“Bristol Myers Squibb will honor legitimate requests for clinical trial data from qualified researchers with a clearly defined scientific objective.”

Data availabilityFind in source

WARNReviewer 2· 85% conf

Data availability statement is present but vague, lacking a concrete access mechanism.

Evidence

“Bristol Myers Squibb will honor legitimate requests for clinical trial data from qualified researchers with a clearly defined scientific objective.”

Data availabilityFind in source

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineINADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Reporting is transparent with trial registration, limitations, and proportional conclusions.

Evidence

“Clinical trials.gov identifier: NCT04109066”

AbstractFind in source

DiscussionFind in source

“This study was sponsored and funded by Bristol Myers Squibb”

AcknowledgementsFind in source

PASSReviewer 2· 90% conf

Reporting is transparent with trial registration, limitations discussed, and proportional conclusions.

Evidence

“Clinical trials.gov identifier: NCT04109066 (https://clinicaltrials.gov/study/NCT04109066)”

AbstractFind in source

DiscussionFind in source

“This study was sponsored and funded by Bristol Myers Squibb”

AcknowledgementsFind in source

Registered (1 ID: ClinicalTrials.gov). No reporting guideline cited.

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 33 references by DOI: 31 verified — 2 no DOI (shown, not verified).

2 data/code links checked; 2 live.

Copyediting

6 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 6 minor suggestions below.

6 copyedit issues flagged: mostly consistency, clarity, typo.

Kaimen Rigor Action ItemsFinal pass before journal submission

1.
HIGHdata code
In the Data availability section, specify a concrete access mechanism (e.g., a data-sharing platform like Vivli or a data access committee) and the timeframe for responding to requests.
The current statement is vague and does not provide a clear route for qualified researchers to obtain the data, which is a reporting gap.
2.
HIGHreporting
In the Discussion, temper the claim of a 'new treatment paradigm' to reflect that long-term benefit (EFS) is not yet established due to short follow-up and the exploratory nature of EFS.
The claim is overstated given the evidence; the paper itself notes longer follow-up is needed.
3.
MEDIUMreporting
In the Methods, explicitly name the statistical software (e.g., SAS version, R version) used for analyses.
This improves reproducibility and was flagged by both reviewers as a minor omission.
4.
MEDIUMreporting
In the Methods or Reporting Summary, explicitly state adherence to CONSORT guidelines for reporting randomized trials, or provide the completed CONSORT checklist.
This strengthens the reporting transparency and is a common expectation for RCTs.
5.
MEDIUMreporting
In the Discussion, add a sentence acknowledging the lack of independent replication of the biomarker findings.
This addresses the limitations_addressed criterion and provides a more balanced interpretation.
6.
MEDIUMreporting
In the Methods, clarify how outliers or missing data were handled in the analysis (e.g., imputation methods) beyond the exclusion of 11 patients due to site closure.
This strengthens the outlier_handling criterion and transparency.
7.
MEDIUMdata code
In the Data availability section, mention whether the study protocol and statistical analysis plan are available in a public repository.
This would allow independent verification of pre-specified analyses.
8.
MEDIUMreporting
In the Results, report the number of patients with missing biomarker data for each assay to enhance transparency.
This helps readers assess potential bias in biomarker analyses.
9.
LOWcopyedit
In the Abstract, change 'Clinical trials.gov identifier' to 'ClinicalTrials.gov identifier' for consistency.
Minor capitalization inconsistency flagged by the copyedit pass.
10.
LOWcopyedit
In the Methods, add a reference for the safety concern about combining abemaciclib with nivolumab.
The statement is unsupported without a citation.
11.
LOWcopyedit
In Table 1, ensure the formatting is consistent, particularly the PD-L1+ columns for the placebo arm.
The table appears to have missing cells, which could confuse readers.
12.
LOWcopyedit
In the Results, clarify the definition of PD-L1+ tumors to avoid redundancy.
Minor wording redundancy flagged by the copyedit pass.

Full text (52,423 chars)Analyzed: Aug 15, 2026